Gastrointestinal Cancer

January 21, 2023

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

January 20, 2023

Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.

January 19, 2023

The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.

January 16, 2023

At a median follow-up of 40 months, patients with unresectable, progressive neuroendocrine pancreatic tumors achieved an 80% progression-free survival rate with Lutathera.

January 11, 2023

The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer.

January 09, 2023

Adjuvant treatment with hepatic arterial infusion chemotherapy-infused FOLFOX improved disease-free survival rates for patients with hepatocellular carcinoma with microvascular invasion.

January 07, 2023

A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.

January 02, 2023

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

December 22, 2022

The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.

December 06, 2022

Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.